OncoMatch/Clinical Trials/NCT07332247
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC
Is NCT07332247 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for nasopharangeal cancer.
This phase II randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus selective re-irradiation in locally advanced recurrent nasopharyngeal carcinoma. The study aims to determine whether sequential radiotherapy provides additional survival benefit beyond systemic immunochemotherapy.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: chemotherapy plus PD-1 inhibitor — recurrent
Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy
Cannot have received: radiotherapy, chemotherapy, immunotherapy, or biological therapy
No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent nasopharyngeal carcinoma
Cannot have received: PD-1/PD-L1 or CTLA-4 inhibitors
Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors
Cannot have received: anti-tumor therapy for recurrent nasopharyngeal carcinoma (including radiotherapy, chemotherapy, surgery, or immunotherapy)
Prior anti-tumor therapy for recurrent nasopharyngeal carcinoma, including radiotherapy, chemotherapy, surgery, or immunotherapy
Lab requirements
Blood counts
hemoglobin ≥ 90 g/l，anc ≥ 1.5 × 10⁹/l，platelet count ≥ 100 × 10⁹/l
Kidney function
creatinine ≤ 1.5 × uln, or creatinine clearance (crcl) / egfr ≥ 60 ml/min
Liver function
total bilirubin ≤ 1.5 × uln，ast and alt ≤ 2.5 × uln, or ≤ 5 × uln in the presence of liver metastases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07332247 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify